Physician profile
Brandon Humble
NPI 1891158341
$7,436.73
in general payments reported to CMS, 2019-2025
28 companies · $2,802 in 2025
The $2,802 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $23.30 · 2022: $309 · 2023: $1,805 · 2024: $1,797 · 2025: $2,802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,249 · Education: $153 · Travel and Lodging: $2.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,249.28 |
| Education | $153.29 |
| Travel and Lodging | $2.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,659.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,337.25 | 2022-2025 | Tezspire, Fasenra, Bevespi Aerosphere |
| Genentech USA, INC. | $777.70 | 2022-2025 | Xolair |
| Regeneron Healthcare Solutions, INC. | $631.15 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $443.90 | 2022-2025 | Nucala, Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $397.05 | 2024-2025 | |
| Csl Behring | $364.87 | 2022-2025 | Haegarda, Hizentra, Andembry |
| Amgen INC. | $246.01 | 2022-2025 | Tezspire |
| Biocryst US Sales Co., LLC | $231.81 | 2023-2025 | Orladeyo |
| Blueprint Medicines Corporation | $213.52 | 2024 | Ayvakit |
| Neurent Medical Limited | $162.10 | 2025 | Neuromark Radiofrequency Console, Neuromark System |
| Pharming Healthcare, INC. | $159.22 | 2024-2025 | Ruconest |
| Takeda Pharmaceuticals U.S.A., INC. | $123.84 | 2020-2025 | Cuvitru, Takhzyro |
| Ars Pharmaceuticals Operations, INC. | $95.31 | 2025 | Neffy |
| Genentech, INC. | $94.38 | 2023-2025 | Xolair |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $93.88 | 2023-2025 | |
| Kaleo, INC. | $68.62 | 2023 | Auvi-Q |
| Grifols USA, LLC | $57.28 | 2025 | Xembify |
| Sanofi-Aventis U.S. LLC | $54.95 | 2024 | |
| Galderma Laboratories, L.P. | $37.19 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.73 | 2023 | Spiriva Respimat |
| Nestle Healthcare Nutrition INC. | $32.05 | 2023 | |
| Paratek Pharmaceuticals, INC. | $25.43 | 2025 | Xhance |
| Lilly USA, LLC | $20.76 | 2025 | Ebglyss |
| Hikma Pharmaceuticals USA | $19.47 | 2025 | Ryaltris |
| Merck Sharp & Dohme LLC | $18.74 | 2023 | |
| Seqirus USA INC | $17.83 | 2025 | Fluad, Flucelvax |
| Ionis Pharmaceuticals, INC. | $17.66 | 2025 | Dawnzera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Humble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.